Supernus Pharmaceuticals Long-Term Investments 2011-2024 | SUPN
Supernus Pharmaceuticals long-term investments from 2011 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
Supernus Pharmaceuticals Annual Long-Term Investments
(Millions of US $) |
| 2023 |
$17 |
| 2022 |
$94 |
| 2021 |
$119 |
| 2020 |
$350 |
| 2019 |
$592 |
| 2018 |
$419 |
| 2017 |
$134 |
| 2016 |
$75 |
| 2015 |
$55 |
| 2014 |
$20 |
| 2013 |
$9 |
| 2012 |
$ |
| 2011 |
$ |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Long-Term Investments
(Millions of US $) |
| 2024-09-30 |
|
| 2024-06-30 |
|
| 2024-03-31 |
$12 |
| 2023-12-31 |
$17 |
| 2023-09-30 |
$25 |
| 2023-06-30 |
$37 |
| 2023-03-31 |
$54 |
| 2022-12-31 |
$94 |
| 2022-09-30 |
$132 |
| 2022-06-30 |
$147 |
| 2022-03-31 |
$125 |
| 2021-12-31 |
$119 |
| 2021-09-30 |
$405 |
| 2021-06-30 |
$445 |
| 2021-03-31 |
$417 |
| 2020-12-31 |
$350 |
| 2020-09-30 |
$388 |
| 2020-06-30 |
$359 |
| 2020-03-31 |
$535 |
| 2019-12-31 |
$592 |
| 2019-09-30 |
$596 |
| 2019-06-30 |
$594 |
| 2019-03-31 |
$523 |
| 2018-12-31 |
$419 |
| 2018-09-30 |
$460 |
| 2018-06-30 |
$503 |
| 2018-03-31 |
$175 |
| 2017-12-31 |
$134 |
| 2017-09-30 |
$123 |
| 2017-06-30 |
$105 |
| 2017-03-31 |
$89 |
| 2016-12-31 |
$75 |
| 2016-09-30 |
$67 |
| 2016-06-30 |
$68 |
| 2016-03-31 |
$69 |
| 2015-12-31 |
$55 |
| 2015-09-30 |
$44 |
| 2015-06-30 |
$33 |
| 2015-03-31 |
$27 |
| 2014-12-31 |
$20 |
| 2014-09-30 |
$16 |
| 2014-06-30 |
$15 |
| 2014-03-31 |
$12 |
| 2013-12-31 |
$9 |
| 2013-09-30 |
$15 |
| 2013-06-30 |
$16 |
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
$2 |
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.089B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
